250 related articles for article (PubMed ID: 36726971)
1. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
De Matteis S; Dicataldo M; Casadei B; Storci G; Laprovitera N; Arpinati M; Maffini E; Cortelli P; Guarino M; Vaglio F; Naddeo M; Sinigaglia B; Zazzeroni L; Guadagnuolo S; Tomassini E; Bertuccio SN; Messelodi D; Ferracin M; Bonafè M; Zinzani PL; Bonifazi F
Front Immunol; 2022; 13():1058126. PubMed ID: 36726971
[TBL] [Abstract][Full Text] [Related]
2. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
3. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
Schoeberl F; Tiedt S; Schmitt A; Blumenberg V; Karschnia P; Burbano VG; Bücklein VL; Rejeski K; Schmidt C; Busch G; von Bergwelt-Baildon M; Tonn JC; Schmitt M; Subklewe M; von Baumgarten L
Blood Adv; 2022 May; 6(10):3022-3026. PubMed ID: 35042236
[TBL] [Abstract][Full Text] [Related]
5. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells.
Storci G; De Felice F; Ricci F; Santi S; Messelodi D; Bertuccio SN; Laprovitera N; Dicataldo M; Rossini L; De Matteis S; Casadei B; Vaglio F; Ursi M; Barbato F; Roberto M; Guarino M; Asioli GM; Arpinati M; Cortelli P; Maffini E; Tomassini E; Tassoni M; Cavallo C; Iannotta F; Naddeo M; Tazzari PL; Dan E; Pellegrini C; Guadagnuolo S; Carella M; Sinigaglia B; Pirazzini C; Severi C; Garagnani P; Kwiatkowska KM; Ferracin M; Zinzani PL; Bonafè M; Bonifazi F
J Clin Invest; 2024 Jun; ():. PubMed ID: 38833312
[TBL] [Abstract][Full Text] [Related]
6. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
7. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
8. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Front Immunol; 2022; 13():877477. PubMed ID: 35464403
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome.
Butt OH; Zhou AY; Caimi PF; Luckett PH; Wisch JK; Derenoncourt PR; Lee K; Wu GF; de Lima MJG; Campian JL; Frank MJ; DiPersio JF; Ghobadi A; Ances BM
JAMA Oncol; 2022 Nov; 8(11):1652-1657. PubMed ID: 36048456
[TBL] [Abstract][Full Text] [Related]
10. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
[TBL] [Abstract][Full Text] [Related]
11. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.
Gust J; Rawlings-Rhea SD; Wilson AL; Tulberg NM; Sherman AL; Seidel KD; Wu QV; Park JR; Gardner RA; Annesley CE
Blood Adv; 2023 Mar; 7(6):1001-1010. PubMed ID: 36006611
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
14. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y; Jie X; Nian L; Wang Y; Wang C; Ma J; Jiang J; Wu Q; Qiao J; Chen W; Cao J; Yan Z; Shi M; Cheng H; Zhu F; Sang W; Li D; Chen C; Xu K; Li Z
Front Immunol; 2023; 14():1169071. PubMed ID: 37153543
[TBL] [Abstract][Full Text] [Related]
15. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
16. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
[TBL] [Abstract][Full Text] [Related]
17. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
18. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
